
Severe symptomatic aortic stenosis (SAS) patient pathway tool

Your evaluation matters

Patients trust you to know the signs and when to act



PARTNER 3 Trial 1 year outcome**	TAVI	Surgery
Death	1%	2.5%
All stroke	1.2%	3.1%

All-cause death, all stroke, and rehospitalization at 1 year: 8.5% TAVI vs 15.1% for surgery $P_{\text{superiority}}\!=\!0.001$

*The PARTNER 3 Trial, SAPIEN 3 TAVI proven superior to surgery on the primary endpoint all-cause death, all stroke, and rehospitalization⁺ and multiple pre-specified secondary endpoints.

**Excludes multiplicity adjustment

*Rehospitalization (valve-related or procedure-related and including heart failure)

SAPIEN 3 TAVI is a proven superior* option to surgery in your low-risk patients like Susan.



Susan, age 73 Low surgical risk

VTAVI Patient

AS disease progression: Severe AS, symptoms include decreased exercise tolerance

NYHA class: II

Fraility indicators: 0

Surgical risk score: 2

Comorbidities: None

QoL expectations: Retired nurse who enjoys frequent travel, working out, and bike rides. She looks forward to an extended life expectancy due to her age and active lifestyle.



David, age 81 Intermediate surgical risk



AS disease progression: Severe AS, symptoms include fatigue, dyspnea upon exertion

NYHA class: III

Fraility indicators: Passed 3 out of 4 with exception of grip test

Surgical risk score: 6

Comorbidities: Diabetes, high blood pressure, previous PCI. No other comorbidities.

QoL Expectations: Semi-retired executive for an insurance company. Enjoys walking trails around his home and playing with his grandkids.



Patricia, age 88 High surgical risk



AS disease progression: Severe AS, symptoms include reduced mobility and inability to walk short distances

NYHA class: III

Fraility indicators: Failed 4/4

Surgical risk score: 10

Comorbidities: Oxygen-dependent COPD, hypertension, and previous pacemaker implantation due to sick sinus syndrome.

QoL Expectations: Retired teacher, and requires assistance in daily life activities.

These are a portrayal of typical TAVI patients and not real patients.

Guide your patients to the best chance at a superior* outcome. Partner with a local heart team. Visit: HeartValves.ca

*The PARTNER 3 Trial, SAPIEN 3 TAVI proven superior to surgery on the primary endpoint allcause death, all stroke, and rehospitalization⁺ and multiple pre-specified secondary endpoints. *Rehospitalization (valve-related or procedure-related and including heart failure)

© 2022 Edwards Lifesciences Corporation. All rights reserved. PP--CAN-1980 v3.0

Edwards Lifesciences • e1919 Minnesota Ct #501, Mississauga, ON L5N 1P8 CANADA • edwards.com





The Medical Technology Association of Canada ("Medtech Canada") is dedicated to advancing healthcare through innovative technologies, devices and diagnostics ("technologies"). Medtech Canada believes that access to high quality, cost-effective healthcare technology is paramount to the improvement of patient care. Medtech Canada represents companies that design, develop, manufacture and market medical technologies and related services used in the treatment, mitigation, diagnosis or prevention of a disease or abnormal physical condition.

The Medtech Canada Code of Conduct is designed to ensure that all relationships between Companies and Healthcare Professionals are governed by the highest ethical standards. By adhering to these carefully developed guidelines, Companies create a win-win situation. Their vital relationships with Healthcare Professionals are safeguarded, legitimate business practices are affirmed and patients across Canada benefit from vital and innovative collaboration between Healthcare Professionals and the medical technology industry.

For a copy of the Medtech Canada Code of Conduct visit: www.medtechcanada.org/page/code

Edwards, Edwards Lifesciences, the stylized E logo, Edwards Commander, Edwards SAPIEN, Edwards SAPIEN XT, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, PARTNER, PARTNER 3, SAPIEN, SAPIEN XT, SAPIEN 3, and SAPIEN 3 Ultra are trademarks or service marks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.